The ability of insulin to stimulate protein synthesis and cellular growth is mediated through the insulin receptor (IR), which phosphorylates Tyr residues in the insulin receptor substrate-signaling proteins (IRS-1 and IRS-2), Gab-1, and Shc. These phosphorylated substrates directly bind and activate enzymes such as phosphatidylinositol 3-kinase (PI3K) and the guanine nucleotide exchange factor for p21
One of the principal endpoints of insulin action is the stimulation of protein synthesis. Insulin induces both a general increase in the rate of mRNA translation and preferential increases in the translation of specific mRNAs (37) . Insulin appears to regulate both the initiation and elongation phases of translation by altering the phosphorylation of initiation factors (eIF2, eIF2B, eIF3, eIF4B, eIF4E, and eIF4G), elongation factors (eEF1 and eEF2), and modulatory proteins.
General protein synthesis is governed in part by eIF2. The activity of this factor can be regulated through the phosphorylation of its ␣ subunit (19) , which is diminished by insulin. eIF2 activity is also regulated by phosphorylation of the ε subunit of the guanine nucleotide exchange factor eIF2B (54) by glycogen synthase kinase-3, which is in turn inactivated by phosphorylation in response to insulin (37) . Another insulinregulated factor affecting general protein synthesis appears to be eEF2 (55) .
Insulin also regulates the specific translation of a small subset of cellular mRNAs which have been termed growth regulated (5) . This regulation is sensitive to the macrolide rapamycin, which was originally characterized as an inhibitor of cell cycle progression through G 1 (reviewed in reference 10). These growth-regulated mRNAs include mRNAs with polypyrimidine tracks at their extreme 5Ј termini (e.g., those encoding ribosomal proteins, eEF1A, eEF2, and insulin-like growth factor II) and mRNAs rich in secondary structure (e.g., those for FGF-5, c-Myc, and ornithine decarboxylase). High levels of secondary structure make these mRNAs strongly dependent on the eIF4 factors, which collectively recognize the mRNA cap, unwind secondary structure, and recruit mRNA to the ribosome (44, 57, 64) . Insulin regulates the cap-binding protein eIF4E in two ways. First, it increases phosphorylation of eIF4E itself, enhancing its affinity for the cap structure of mRNA (45) . Second, it increases phosphorylation of PHAS-I (also called 4E-BP), a protein which, in the unphosphorylated state, binds to eIF4E (40, 53) ; this interferes with the binding of eIF4E and eIF4G and thereby blocks cap-dependent initiation of translation (33) . The insulin-induced phosphorylations of both PHAS-I (6, 11, 22, 41, 43) and eIF4E (43) are sensitive to rapamycin.
Insulin receptor (IR) and IRS-1 are required for the insulinmediated stimulation of both general and growth-regulated protein synthesis (43) as well as DNA synthesis (69) and p70 S6K activation (47) . Phosphatidylinositol 3Ј-kinase (PI3K) appears to be the only phosphotyrosine-activated effector downstream of IRS-1 that is required for stimulation of protein (43) and DNA (49) synthesis. The phosphorylation of glycogen synthase kinase-3 is mediated by the Ser/Thr protein kinase Akt (also called PKB) (16) , which is itself activated by PI3K (29, 30) . Similarly, the rapamycin-sensitive pathway leading to insulin-stimulated phosphorylation of PHAS-I proceeds through PI3K and Akt and also results in activation of p70 S6K (14) .
To characterize further the downstream effectors of IRS-1 for insulin-stimulated protein synthesis, we used a panel of cells which differ in the key components of the insulin signaling system they contain. 32D is a myeloid progenitor cell line which is dependent on interleukin 3 (IL-3) but insensitive to insulin (69) . 32D cells contain little endogenous insulin receptor (IR) and completely lack IRS-1 and IRS-2, but ectopic expression of IR and IRS-1 permits cells to respond to insulin PKC and MAPK. TPA, in the absence of insulin, partially activated protein synthesis in IR/IRS-1 cells (Fig. 1A, column  4 ). The addition of insulin and TPA together produced the same response as insulin alone (column 6 versus column 3), suggesting that the pathways for insulin and TPA are redundant rather than synergistic or additive. TPA also overcame the inhibition of insulin-stimulated protein synthesis by the PI3K inhibitor wortmannin (column 7 versus column 5). These results suggest that the TPA-stimulated component is either downstream of PI3K or on a parallel but convergent pathway, i.e., activating the same translational factor(s).
To differentiate between isoforms of PKC in insulin-stimulated protein synthesis, we performed two kinds of experiments. First, we tested 32D cells for the presence of the known isoforms of PKC by Western analysis (Fig. 2 ). Second, we tested various PKC inhibitors: Gö 6976, which inhibits the "classical" (␣ and ␤) and "new" (␦ and ε) PKCs but not the "atypical" isoforms (42); bisindolylmaleimide, which inhibits all isoforms of PKC except the atypical ones at concentrations less than 10 Ϫ6 M (42); and staurosporine, a potent but unselective inhibitor of all PKCs (32, 65) . Only staurosporine inhibited insulin-stimulated protein synthesis (Fig. 1B) , whereas all three inhibited TPA-stimulated protein synthesis (Fig. 1C) . Taking together the results of immunoanalysis and testing with isoform-specific inhibitors, we can conclude that PKC␣, -␤, -␥, -␦, -ε, -, and -are not responsible for insulinstimulated translation since (i) the classical PKCs are at very low levels or are nonexistent in 32D cells compared with brain cells and are sensitive to the specific inhibitors; (ii) PKC␦ is present in 32D cells but is sensitive to the specific inhibitors; (iii) PKC␥ is at very low levels in 32D cells but is not activated by PI3K (68) , whereas insulin-stimulated protein synthesis is (43) ; and (iv) PKCε and PKC are not present in 32D cells. On the other hand, PKC, PKC, and PKC, which are all members of the atypical group of PKCs and which have very similar amino acid sequences (GenBank accession no. L18964 and X72973), are present in 32D cells and not inhibited by the isoform-specific inhibitors used. These results suggest that insulin stimulates protein synthesis by activating one or more atypical isoforms of PKC. The observed stimulation of protein synthesis and compensation of PI3K inhibition by TPA (Fig.  1A ) may indicate that classical PKCs can substitute for insulinstimulated atypical PKCs on a parallel pathway.
Insulin activates PKC in an IRS-1-and PI3K-dependent manner. A direct assay confirmed that an atypical PKC isoform, PKC, was indeed activated by both IL-3 and insulin (Fig. 3A, columns 2 and 3) . The insulin response required the presence of IRS-1 (Fig. 3A , column 6 versus column 3) and was inhibited by the addition of wortmannin (Fig. 3B) . Moreover, an IRS-1 variant in which all 18 potentially phosphorylated Tyr residues were replaced by Phe (IRS-1 F18 ) (49) failed to activate PKC (Fig. 3C, column 3 ), but a variant in which the three Tyr residues which bind and activate PI3K were restored to IRS-1 F18 (IRS-1 Y608-658 ) (49) activated PKC (Fig. 3C, column  9 ). This indicates that PKC is downstream of IRS-1 and PI3K but not of other pathways activated by the IR, e.g., the Shcmediated activation of p21
Ras . Overexpression of constitutively activated PKC in the absence of IRS-1 supports protein synthesis but not cell cycle progression. For more direct evidence of a cause-and-effect relationship between PKC and stimulation of protein synthesis, we transfected 32D cells with cDNA encoding a constitutively active form of PKC fused to glutathione S-transferase (⌬PKC) (21) . ⌬PKC contains the catalytic domain of PKC, which is 84% identical to that of the other atypical PKC isoforms, and . Evidence for the expression of ⌬PKC is provided by the demonstration of a GSH-binding protein that phosphorylated myelin basic protein ( Fig. 3D) and that crossreacted with anti-PKC antibodies (Fig. 3D, inset) . ⌬PKC was active in the absence of either IL-3 or insulin (Fig. 3E , column 4).
General protein synthesis was stimulated by insulin in IR/-/ ⌬PKC cells to the same extent as in IR/IRS-1 cells (Fig. 4A) , indicating that the IRS-1 dependence is entirely replaced by PKC. The fact that protein synthesis in the IR/-/⌬PKC cells still required insulin suggests that an additional IR-driven pathway(s) is necessary, e.g., Shc activation of MAPK. Coexpression of IRS-1 and ⌬PKC only slightly increased overall protein synthesis (Fig. 4A ), as would be expected if PKC were in the IRS-1 pathway for protein synthesis stimulation. DNA synthesis, on the other hand, was not supported by the presence of ⌬PKC, either alone or in conjunction with insulinactivated IR (Fig. 4B ), suggesting that other IRS-1-mediated events are required. Since the IRS-1 Y608-658 variant supports IRS-1-mediated DNA synthesis (49), the missing activity for DNA synthesis is an effector downstream of PI3K other than PKC.
Depletion of MAPK with antisense oligodeoxynucleotides prevents insulin-stimulated protein synthesis. Previous studies showed that MAPK activation is not sufficient for insulinstimulated protein synthesis (43) . Also, MAPK activation by IRS-1 is not necessary for insulin-stimulated protein synthesis (43) . We therefore tested whether MAPK activation (by any pathway) was necessary for insulin-stimulated protein synthesis. We prevented the expression of p44 and p42 MAP kinases by electroporating antisense phosphorothioate oligonucleotide analogs complementary to the 5Ј-untranslated region of MAPK mRNAs (59) . IR/IRS-1 cells became unresponsive to insulin after depletion of MAPK (Fig. 5) . This indicates that insulin-induced activation of MAPK, presumably via Shc (48, 52, 72) , is necessary for the stimulation of protein synthesis.
Overexpression of PKC does not affect p70 S6K activity. In IR/IRS-1 cells, insulin causes phosphorylation and consequent activation of p70 S6K , but this does not occur in IR/-cells (47) . To test whether ⌬PKC substitutes for this activity of IRS-1, we measured p70 S6K activation in IR/IRS-1, IR/IRS-1/⌬PKC, IR/-, and IR/-/⌬PKC cells (Fig. 6) . The results indicated that the expression of ⌬PKC did not alter insulin-stimulated phosphorylation and activation of p70 S6K in either the presence or absence of IRS-1. Thus, PKC is not sufficient to activate p70 activation (Fig. 6) suggests that insulin and PKC are mediating stimulation of general but not growth-regulated (rapamycin-sensitive) protein synthesis. To test this hypothesis, we measured the synthesis of a rapamycin-insensitive protein, actin (43) , and a rapamycin-sensitive, growth-regulated protein, c-Myc (17, 43) . Constitutively active PKC, in conjunction with insulin, stimulated actin synthesis, regardless of whether IRS-1 was present (Fig. 7A) . Insulin-stimulated c-Myc synthesis, on the other hand, required IRS-1 (Fig. 7B, lane 9 versus lane 3) , and this requirement was not replaced by ⌬PKC (lane 6). These changes in c-Myc and actin protein levels were due to changes at the translational level, since mRNAs for c-Myc and actin were nearly the same regardless of treatment ( Fig. 7C ; quantitation given in the figure legend). This is consistent with earlier results showing that rapamycin treatment of IR/IRS-1 cells prevents the insulin stimulation of c-Myc but not actin synthesis (43) .
DISCUSSION
To understand the effects of insulin on protein synthesis and the signaling pathways involved, it is necessary to differentiate between the translation of housekeeping and growth-regulated mRNAs (5, 10, 35, 56) . Overexpression of eIF4E causes rapid growth and cellular transformation (18, 39) and specifically increases the translation of growth-regulated mRNAs whose products are required for cell cycle progression, e.g., ornithine FIG. 5 . Insulin-stimulated translation requires MAPK. IR/IRS-1 cells were electroporated with phosphorothioate oligonucleotides (59) corresponding to nucleotides 25 to 41 of mouse MAPK (S) or with the corresponding antisense probe (AS) or were mock treated (C). Cells were grown in the presence of the oligonucleotides (1 M) for the indicated times, after which MAPK expression was determined by Western blotting (inset) and stimulation of protein synthesis by insulin was determined as described in the legend for Fig. 1 (bars) .
FIG. 6. Expression of ⌬PKC does not affect p70
S6K activation. The indicated 32D cell lines in log phase were washed and starved for IL-3 and were treated with 100 nM insulin (I) or IL-3 or were left untreated (C) for 25 min at 37°C. Then they were diluted in ice-cold PBS and collected by centrifugation. Measurements of p70 S6K activity by Western blotting were performed as described in Materials and Methods. decarboxylase (63) , ornithine aminotransferase (24), cyclin D1 (58), P23 (9), NF-AT (4), c-Myc (17) , and FGF (36) . This preferential stimulation of translation is thought to be related to the presence of extensive secondary structure at the 5Ј-untranslated regions of growth-regulated mRNAs and the role of initiation factors of the eIF4 group in unwinding mRNA secondary structure (44, 57, 64) . Translational regulation of housekeeping mRNAs, on the other hand, is likely to involve components which are equally required for translation of all mRNAs, e.g., active 43S initiation complexes. Studies to date indicate that insulin stimulates translation of both growthregulated and housekeeping mRNAs (37) .
The signaling pathways by which insulin stimulates growthregulated protein synthesis are partially understood. Both types of protein synthesis have a common requirement for IR and IRS-1 (43) (Fig. 7) . The only phosphotyrosine-mediated signal from IRS-1 necessary for protein synthesis is that which activates PI3K, since the IRS-1 Y608-658 variant stimulates both general and growth-regulated protein synthesis (43) . MAPK activation does not play a role in the IRS-1-mediated pathway to protein synthesis, since an IRS-1 variant unable to activate MAPK (48) nonetheless activates protein synthesis (43) . Moreover, MAPK activation in the absence of PI3K activation does not support stimulation of protein synthesis, since insulin activates MAPK (48) but not protein synthesis (43) in IR/-cells.
At some point after PI3K, the pathways to growth-regulated and general protein synthesis diverge, as demonstrated by the use of the fungal macrolide rapamycin. Activation of a rapamycin-sensitive pathway, most commonly measured by the activation of p70 S6K (15) , is required for growth-regulated but not general protein synthesis. Rapamycin specifically prevents increased synthesis of highly cap-dependent, growth-regulated mRNAs by both insulin (43) and other growth factors (6, 35, 51, 67) . Rapamycin blocks the phosphorylation of PHAS-I (6, 11, 22, 41, 43) and eIF4E (43) , although blocking the phosphorylation of the latter could be an indirect effect since PHAS-I binding prevents eIF4E phosphorylation by PKC in vitro (71) . Yet the findings that eIF4E phosphorylation in CHO cells overexpressing IR is sensitive to MEK inhibitors (28) and that PHAS-I and eIF4E phosphorylations appear to be regulated independently in 293 cells (26) and 32D cells (43) suggest distinct pathways to eIF4E and PHAS-I. In any case, preventing both PHAS-I and eIF4E phosphorylation renders eIF4E less active or less available for participation in the translation of highly cap-dependent mRNAs. Rapamycin, however, does not prevent insulin-stimulated general protein synthesis or the synthesis of a typical housekeeping protein, actin (43) . Thus, rapamycin can serve as a discriminator between general and growth-regulated protein synthesis.
Activation of the rapamycin-sensitive pathway by insulin is downstream of PI3K (13, 14) . The Ser/Thr protein kinase Akt is on the pathway from PI3K to p70 S6K activation by both insulin (12) and platelet-derived growth factor (30) , and, in fact, Akt can be activated by direct interaction with phosphatidylinositol-3,4-bisphosphate and phosphatidylinositol-3,4,5-trisphosphate, the products of PI3K (29) . The actual rapamycin-sensitive component is downstream from Akt. Rapamycin binds to the 12-kDa protein FKBP, which in turn binds to a novel protein kinase called TOR (3) or mTOR in mammalian systems (reference 11 and references therein). mTOR is on the pathway to PHAS-I phosphorylation (2, 6, 11, 41) . Rapamycin also inhibits DNA synthesis and cell cycle progression through G 1 (15, 38, 66) . These two effects of rapamycin, inhibition of highly cap-dependent, growth-regulated mRNA translation and inhibition of cell cycle progression, can be accommodated in a model whereby increasing the activity and availability of eIF4E yields products (cyclins and transcription factors, etc.) that promote cell division. An elegant demonstration of the link between the translational and mitogenic roles of TOR has been published (3) .
In contrast to the wealth of information about the rapamycin-sensitive branch of insulin signaling, relatively little is known about the pathway from PI3K that controls general protein synthesis. Notably, insulin still stimulates protein synthesis when the rapamycin-sensitive pathway is blocked (43) . The signal, which accounts for approximately 90% of insulinstimulated protein synthesis, emanates from PI3K but is independent of TOR (Fig. 8) . The results presented in this study indicate that this pathway involves PKC. Insulin is capable of activating PKC through IRS-1 and PI3K (Fig. 3) . Furthermore, constitutively active PKC is able to functionally replace IRS-1 in the stimulation of general protein synthesis (Fig. 4A  and 7A ). More specifically, PKC functionally replaces the ability of IRS-1 to activate PI3K, since IRS-1 Y608-658 , which contains only the Tyr residues which activate PI3K (49), was able to fully activate PKC (Fig. 3C) . However, PKC replaces some but not all functions of PI3K: general protein synthesis and actin synthesis are supported ( Fig. 4A and 7A) but not growth-regulated protein synthesis, as exemplified by c-Myc (Fig. 7B) , activation of p70 S6K (Fig. 6 ), or cell cycle progression (Fig. 4B) . This result agrees with the finding that expression of constitutively active or dominant-negative forms of PKC does not affect the activation of p70 S6K by serum (8) . Thus, it seems likely that PI3K is independently activating two different pathways involved in protein synthesis: the atypical PKC pathway for general protein synthesis and the Akt pathway for growthregulated protein synthesis (Fig. 8) .
Atypical PKC isoforms are thus named because they are neither activated nor down-regulated by phorbol esters, unlike other PKC isoforms (20) . Previous studies have indicated that platelet-derived growth factor activates PKC, another atypical PKC, through a mechanism involving PI3K (1) and that IL-4, acting through PI3K, causes PKC translocation from the cytosolic to the membrane fraction (34) . In the case of insulin, it has been shown that the levels of both classical and atypical PKCs decrease in cytosolic locations and increase in membrane locations after insulin treatment of rat adipocytes (25) . PKC is unlikely to be downstream of Akt, however, since phosphatidylinositol-3,4-bisphosphate and phosphatidylinositol-3,4,5-trisphosphate directly activate PKC (50) . It is more likely that PI3K activates Akt and PKC independently, in both cases secondary to the synthesis of phosphatidylinositides in the plasma membrane.
A number of previous studies have shown an effect of phorbol esters and nonspecific PKC inhibitors on the phosphorylation of members of the eIF4 group initiation factors (reference 27 and references therein). By contrast, there have been relatively few studies on the involvement of PKC in general protein synthesis. In Swiss 3T3 fibroblasts, down-regulation of classical PKC with phorbol esters prevented the insulin response as did a general PKC inhibitor (70) . However, in the 32D cell system (IR/IRS-1 cells), pretreatment with phorbol esters only slightly diminished the insulin response (data not shown). This discrepancy may be due to differences in the cell types employed. In any case, the interpretation of experiments in which PKC is down-regulated is complicated by the fact that down-regulation of PKC also inhibits the ability of insulin to stimulate GRB-2/SOS and the consequent downstream activation of MAPK (60) . As discussed below, MAPK is required for insulin-stimulated protein synthesis, independent of the IRS-1 signaling system.
The experiments presented here indicate that insulin-stimulated general protein synthesis occurs through atypical and not classical PKCs. First, we show that wortmannin inhibits insulin-stimulated protein synthesis (43) (Fig. 1A, column 5 ), yet the stimulation by TPA plus insulin is not blocked by wortmannin (Fig. 1A, column 7) . This indicates that the TPA signal is not proceeding through PI3K but rather through a parallel pathway. Second, classical PKCs are at very low levels in 32D cells (Fig. 2) . Third, Gö 6976 and bisindolylmaleimide, which inhibit all PKC isoforms except the atypical ones (42), failed to prevent the insulin-stimulated response, while a general PKC inhibitor was effective (Fig. 1B ). Yet all three inhibitors prevented TPA-stimulated protein synthesis (Fig. 1C) . We conclude that, although classical PKCs can stimulate general protein synthesis, the pathway is parallel to that of insulin. The atypical PKC, on the other hand, is an essential link in the insulin pathway to general protein synthesis.
It is noteworthy that insulin is still required in cells expressing constitutively active PKC but lacking IRS-1 (Fig. 4A) , suggesting that there is at least one IRS-1-independent pathway emanating from the IR that is required for general protein synthesis in conjunction with PKC. The results presented here indicate that the activation of MAPK is one of these IRmediated events, despite the fact that IRS-1-mediated activation of MAPK does not play a significant role in insulin-stimulated protein synthesis (43) . Depletion of MAPK with an antisense oligonucleotide prevented insulin-stimulated protein synthesis (Fig. 5) . This is similar to the observation that a specific inhibitor of MEK prevents the stimulation of protein synthesis in aortic smooth-muscle cells by growth factors (62) . The precise mechanistic interpretation of the MAPK depletion experiment, however, is not clear. Presumably, targets downstream of MAPK have a positive effect on protein synthesis, but more complicated scenarios involving phenotypic changes that may result from long-term (48-to 76-h) depletion of MAPK activity cannot be ruled out.
We conclude that the insulin signal bifurcates at PI3K (Fig.  8) , one branch leading to general protein synthesis (through PKC) and one, to growth-regulated protein synthesis (through Akt). Although more complex explanations of the data are possible, a consistent, straightforward model is that PI3K generates phosphatidylinositol-3,4-bisphosphate and phosphatidylinositol-3,4,5-trisphosphate in the plasma membrane and that both Akt and PKC are activated by these phospholipids. Our inability to obtain viable cell lines stably expressing a dominant-negative form of PKC (7) is consistent with a requirement of general protein synthesis for cell survival (data not shown). The downstream targets of PKC are expected to be factors equally required for translation of all mRNAs but are not yet known.
